Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19124804http://www.w3.org/2000/01/rdf-schema#comment"

Purpose

We recently demonstrated the biologic importance of the nuclear factor kappa B (NF-kappaB) subunit Rel A in chronic lymphocytic leukemia (CLL) and hypothesized that Rel A DNA binding would have prognostic significance in this disease.

Patients and methods

Rel A DNA binding was quantified in nuclear extracts derived from 131 unselected CLL patient samples using a quantitative DNA-binding enzyme-linked immunosorbent assay-based method. We then investigated the ability of Rel A to predict for the requirement for treatment and survival and compared our findings with other established prognostic markers.

Results

Rel A DNA binding was strongly associated with advanced Binet stage (P < .0001) but did not correlate with immunoglobulin V(H) (IgV(H)) mutation status (P = .25), CD38 expression (P = .87), or zeta-chain-associated protein kinase 70 (ZAP-70) expression (P = .55). It was predictive of time to first treatment (P = .02) and time to subsequent treatment (P = .0001). In addition, Rel A was the most predictive marker of survival both from date of diagnosis (hazard ratio [HR], 9.1; P = .01) and date of entry into the study (HR, 3.9; P = .05) and retained prognostic significance in multivariate analysis for both time to first treatment and overall survival in the presence of Binet stage, IgV(H) mutation status, CD38, and ZAP-70.

Conclusion

Rel A is an independent prognostic marker of survival in CLL and seems to have the unique capacity to predict the duration of response to therapy. Prospective assessment of Rel A as a marker of clinical outcome and as a therapeutic target are now warranted."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.org/dc/terms/identifier"doi:10.1200/jco.2008.19.1114"xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Brennan P."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Pratt G."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Lin T.T."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Pepper C."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Hills R."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Fegan C."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Rowntree C."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Hewamana S."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/author"Karunanithi K."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/date"2009"xsd:gYear
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/name"J Clin Oncol"xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/pages"763-769"xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/title"Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia."xsd:string
http://purl.uniprot.org/citations/19124804http://purl.uniprot.org/core/volume"27"xsd:string
http://purl.uniprot.org/citations/19124804http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19124804
http://purl.uniprot.org/citations/19124804http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19124804
http://purl.uniprot.org/uniprot/#_A0A087X0W8-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
http://purl.uniprot.org/uniprot/#_B4E082-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
http://purl.uniprot.org/uniprot/#_L0R6N5-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
http://purl.uniprot.org/uniprot/#_Q2TAM5-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
http://purl.uniprot.org/uniprot/#_P78359-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
http://purl.uniprot.org/uniprot/#_Q04206-mappedCitation-19124804http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19124804
▶